Mpro

Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research

Retrieved on: 
Tuesday, March 14, 2023
Poster, Conference, Ensitrelvir, Enzyme assay, Viral, Novel, Pan, SARS-CoV-2, Arbutus, International Conference on Emerging Infectious Diseases, Gesellschaft mit beschränkter Haftung, ICAR, Dodi Protero, Virology, Antiviral Research, EC50, Omicron, Therapy, IND, Pharmaceutical industry, Vaccine, Mpro

WARMINSTER, Pa., March 14, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that preclinical data for AB-343, our novel oral SARS-CoV-2 Mpro inhibitor, has been presented in poster format at the 36th International Conference on Antiviral Research (ICAR), in Lyon, France.

Key Points: 
  • “We are excited that our preclinical data for AB-343 has been selected for poster presentation at ICAR.
  • Many of the studies compared AB-343 to nirmatrelvir, the active ingredient in Pfizer’s Paxlovid™ and ensitrelvir, the active ingredient in Shionogi’s Xocova®.
  • The results showed that AB-343 targets SARS-CoV-2 Mpro and inhibits viral replication in vitro (EC50 ~ 20nM).
  • Some of these studies were conducted in part with Proteros biostructures GmbH under the discovery research and license agreement entered into in April 2021.

Anixa Biosciences to Present at Biotech Showcase 2023

Retrieved on: 
Monday, December 19, 2022
Cleveland Clinic, Breast cancer, H. Lee Moffitt Cancer Center & Research Institute, Protein, Sumathi Best Television Current Reporting Award, Annual report, SAN, Biotechnology, Hilton San Francisco Union Square, Ovarian cancer, Cancer, TNBC, Infection, Risk, Disease, Severe acute respiratory syndrome coronavirus 2, COVID-19, Therapy, Mpro, Pharmaceutical industry

SAN JOSE, Calif., Dec. 19, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present at the Biotech Showcase 2023 conference being held in-person on January 9-11, 2023, at the Hilton San Francisco Union Square in San Francisco, California, and virtually on January 18-19, 2023.

Key Points: 
  • SAN JOSE, Calif., Dec. 19, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present at the Biotech Showcase 2023 conference being held in-person on January 9-11, 2023, at the Hilton San Francisco Union Square in San Francisco, California, and virtually on January 18-19, 2023.
  • Biotech Showcase is one of the industry's largest annual healthcare investor and partnering conferences, bringing together biopharmaceutical and life sciences company executives, investors, sector analysts, bankers, and industry stakeholders.
  • More than 350 presentations from mid-, small- and micro-cap public and private companies are expected to present at the event.
  • Qualified investors and buy- and sell-side analysts are invited to request a complimentary registration to attend Biotech Showcase.

Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir B

Retrieved on: 
Tuesday, November 29, 2022
SAN, Wireless ambulatory ECG, CYP3A4, Bilirubin, Therapy, Osteoarthritis, Security (finance), BID, Sciatica, Severe acute respiratory syndrome coronavirus 2, NMPA, Cathepsin L, Pharmacokinetics, TRPV1, PK, User experience, Pain, Patient, Risk, Trial of the century, University of Novi Sad Faculty of Technical Sciences, FDA, Autoimmune disease, SAD, RNA, Phase, Mpro, Toxicity, Postherpetic neuralgia, Annual report, Death, AES, Liver, AUC, Headache, Antibody, RTX, Viral load, Vital signs, PHN, AE, PCR, Cancer, Ritonavir, Vaccine, Generic drug, Copper, Pharmaceutical industry, COVID-19, Safety, Tolerability

There were no severe or serious AEs, no premature discontinuation of STI-1558 due to an AE, and no deaths.

Key Points: 
  • There were no severe or serious AEs, no premature discontinuation of STI-1558 due to an AE, and no deaths.
  • Even the lowest dose produced trough levels significantly above the EC90 value for viral inhibition of STI-1558.
  • A similar Phase I/Ib SAD/MAD study has been fully enrolled in China in both healthy subjects and patients infected with SARS-CoV-2.
  • The liver enzyme elevations occurred late ( 5 days) in study treatment and resolved without the need for any treatment.

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Tuesday, November 8, 2022
Diagnosis, Infection, Ovarian cancer, NASDAQ, Cleveland Clinic, YouTube, Risk, Industry, 2022 Formula One World Championship, Breast, Department, Private Securities Litigation Reform Act, SAN, Immunity, Cancer, Inflammation, Sumathi Best Television Current Reporting Award, Triple-negative breast cancer, TNBC, Immune system, Life, History of Cleveland Clinic, Forward-looking statement, Breast cancer, COVID-19, H. Lee Moffitt Cancer Center & Research Institute, Neoplasm, Ageing, Protein, Tissue, Mpro, Research, International Civil Engineering Symposium, Annual report, Therapy, Severe acute respiratory syndrome coronavirus 2, Technology, Pharmaceutical industry, Vaccine

SAN JOSE, Calif., Nov. 8, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announceda presentation outlining the design of its ongoing breast cancer vaccine trial on December 7, 2022, at the 2022 San Antonio Breast Cancer Symposium.

Key Points: 
  • SAN JOSE, Calif., Nov. 8, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announceda presentation outlining the design of its ongoing breast cancer vaccine trial on December 7, 2022, at the 2022 San Antonio Breast Cancer Symposium.
  • Activating the immune system against this "retired" protein provides preemptive immune protection against emerging breast tumors that express -lactalbumin.
  • The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer specifically triple negative breast cancer (TNBC), the most lethal form of the disease as well as a vaccine to prevent ovarian cancer.
  • These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.

Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 7, 2022
Food, Investor, GLOBE, NASDAQ, Infection, U.S. Securities and Exchange Commission, NCT, Patient, SEC, Private Securities Litigation Reform Act, Board, Disclosure, Regulation, Death, Clinical trial, Forward-looking statement, Regulation Fair Disclosure, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Global health, Intention, COVID, Goal, Board of directors, PRDS, Public expenditure, Medicine, Mpro, Research, Annual report, Security (finance), Risk, Adult, Safety, Therapy, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Pardes

Research and development expenses were $17.4 million for the quarter ended September30, 2022, compared to $8.1 million for the quarter ended September30, 2021, an increase of $9.3 million.

Key Points: 
  • Research and development expenses were $17.4 million for the quarter ended September30, 2022, compared to $8.1 million for the quarter ended September30, 2021, an increase of $9.3 million.
  • General and administrative expenses were $6.9 million for the quarter ended September30, 2022, compared to $3.4 million for the quarter ended September30, 2021, an increase of $3.5 million.
  • Pardes cash and cash equivalents as of September30, 2022, were $209.1 million compared to $228.6 million as of June 30, 2022.
  • Accordingly, investors should monitor Pardes Biosciences Investors website, in addition to following Pardes Biosciences press releases, Securities and Exchange Commission (SEC) filings, public conference calls, presentations and webcasts.

Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland Clinic

Retrieved on: 
Wednesday, October 26, 2022
SAN, LinkedIn, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Risk, Therapy, Triple-negative breast cancer, Life, Inflammation, Woman, Severe acute respiratory syndrome coronavirus 2, Sumathi Best Television Current Reporting Award, Annual report, NASDAQ, Neoplasm, Patient, H. Lee Moffitt Cancer Center & Research Institute, Cleveland Clinic, Twitter, Tissue, Immunity, Mpro, Cancer, Technology, Private Securities Litigation Reform Act, Breast, Immune system, Ovarian cancer, Industry, Department, TNBC, Breast cancer, BRCA1, CEO, Research, Safety, Protein, Recurrence, Forward-looking statement, Ageing, COVID-19, Gene, Pharmaceutical industry, Vaccine, Facebook

SAN JOSE, Calif., Oct. 26, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1b trial for its preventative breast cancer vaccine.

Key Points: 
  • SAN JOSE, Calif., Oct. 26, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1b trial for its preventative breast cancer vaccine.
  • "We are excited to commence the second stage of the Phase 1 trials for our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa.
  • Dr. Tuohy is named as inventor on the technology, which Cleveland Clinic exclusively licensed to Anixa Biosciences.
  • The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer specifically triple negative breast cancer (TNBC), the most lethal form of the disease as well as a vaccine to prevent ovarian cancer.

Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Monday, October 10, 2022
SAN, LinkedIn, Infection, Therapy, SITC, Severe acute respiratory syndrome coronavirus 2, Sumathi Best Television Current Reporting Award, Annual report, NASDAQ, Patient, H. Lee Moffitt Cancer Center & Research Institute, Twitter, Annual general meeting, Immunotherapy, Mpro, Cancer, Technology, Private Securities Litigation Reform Act, Ovarian cancer, Industry, FSHR, TNBC, Society, Breast cancer, Cleveland Clinic, Protein, Forward-looking statement, OVCA, COVID-19, Society for Immunotherapy of Cancer, Risk, Vaccine, Facebook

SAN JOSE, Calif., Oct. 10, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announceda presentation outlining its ovarian cancer CAR-T therapy trial at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting being held November 8-12, 2022.

Key Points: 
  • SAN JOSE, Calif., Oct. 10, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announceda presentation outlining its ovarian cancer CAR-T therapy trial at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting being held November 8-12, 2022.
  • Additional presentation details can be found below:
    Anixa is a clinical-stage biotechnology company with programs addressing cancer and infectious disease.
  • These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.
  • You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections

Retrieved on: 
Tuesday, September 13, 2022
Regulation, PRDS, Investor, Tablet, Safety, Infection, COVID-19, Risk, Severe acute respiratory syndrome coronavirus 2, Intention, Population, Private Securities Litigation Reform Act, Toxicology, Forward-looking statement, Patient, Clinical trial, U.S. Securities and Exchange Commission, Annual report, Nasdaq, Regulation Fair Disclosure, Food, NCT, Death, Coronaviridae, Security (finance), GLOBE, SEC, Mpro, Disclosure, Pharmaceutical industry, Pardes

CARLSBAD, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today reported commencement of a Phase 2 double-blind, randomized study to evaluate the antiviral activity, safety, and efficacy of orally administered PBI-0451 compared with placebo in non-hospitalized symptomatic adults with COVID-19 who are not at increased risk of progressing to severe illness.  

Key Points: 
  • Pardes Biosciences expects to enroll 210 patients in the Phase 2 clinical trial at approximately 75 sites within the United States.
  • We look forward to evaluating PBI-0451 in this broad patient population and sharing preliminary results in the first quarter of 2023.
  • PBI-0451 is a potential stand-alone, novel, direct-acting oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections in Phase 2 clinical development.
  • Accordingly, investors should monitor Pardes Biosciences Investors website, in addition to following Pardes Biosciences press releases, Securities and Exchange Commission (SEC) filings, public conference calls, presentations and webcasts.

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium

Retrieved on: 
Monday, September 12, 2022
Risk, Therapy, AACR, American Association for Cancer Research, COVID-19, Twitter, Infection, Sumathi Best Television Current Reporting Award, Ovarian cancer, Severe acute respiratory syndrome coronavirus 2, LinkedIn, Senior, FSHR, Private Securities Litigation Reform Act, American Association, Industry, Forward-looking statement, Clinical trial, Cleveland Clinic, Cancer, Breast cancer, Technology, Protein, Annual report, TNBC, B cell, NASDAQ, H. Lee Moffitt Cancer Center & Research Institute, SAN, Research, Association, Overalls, Mpro, Vaccine, Facebook

The symposium will include a seminar on immuno-oncology on Wednesday, September 28, 2022, at which Dr. Conejo-Garcia is an invited lecturer.

Key Points: 
  • The symposium will include a seminar on immuno-oncology on Wednesday, September 28, 2022, at which Dr. Conejo-Garcia is an invited lecturer.
  • "Moffitt and Anixa have been working together to advance this ovarian cancer therapy and we are thrilled to have treated the first patient in our ongoing clinical trial.
  • If this therapeutic approach is successful, this could enable a major shift in the overall treatment paradigm for ovarian cancer."
  • You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Wednesday, August 31, 2022
COVID-19, Breast cancer, Technology, Cancer, SAN, NASDAQ, Protein, Risk, Infection, Cleveland Clinic, Sumathi Best Television Current Reporting Award, LinkedIn, Forward-looking statement, TNBC, Mpro, Severe acute respiratory syndrome coronavirus 2, Conference, Therapy, Twitter, Clinical trial, Annual report, Ovarian cancer, Private Securities Litigation Reform Act, Industry, H. Lee Moffitt Cancer Center & Research Institute, Pharmaceutical industry, Facebook

SAN JOSE, Calif., Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 (Hybrid Conference).

Key Points: 
  • SAN JOSE, Calif., Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 (Hybrid Conference).
  • Details of Anixa's presentation are as follows:
    Anixa management will also be available for one-on-one meetings throughout the conference.
  • Anixa is a clinical-stage biotechnology company with a number of programs addressing cancer and infectious disease.
  • You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.